Curcumin for the treatment of attention deficit hyperactivity disorder (ADHD) - a randomised, double-blind, placebo-controlled study

INTERVENTION: Curcumin capsules containing 250‐500mg of a proprietary blend of curcumin (BCM‐95 'Registered Trademark') will be consumed twice daily for 12 weeks by children diagnosed with ADHD or with significant attentional problems. Adherence to capsule intake will be monitored through capsule return and count. CONDITION: Attention deficit hyperactivity disorder (ADHD) PRIMARY OUTCOME: Change in ADHD score as assessed by the ADHD Rating Scale‐IV SECONDARY OUTCOME: Strengths and Difficulties Questionnaire (SDQ). The SDQ is a behavioral screening questionnaire assessing the following areas‐ emotional symptoms, conduct problems, hyperactivity/ inattention, peer relationship problems and prosocial behaviour. INCLUSION CRITERIA: 1. Child is a healthy male or female aged between 6 and 14 years 2. Child has been diagnosed with ADHD or significant attentional problem, as assessed by investigators 3. Child is willing and able to swallow capsules. 4. Preferable, but not essential. Child’s teacher is willing to complete questionnaires (at the beginning and end of the study)